惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

月光博客
月光博客
Martin Fowler
Martin Fowler
博客园_首页
量子位
T
Tailwind CSS Blog
博客园 - Franky
G
Google Developers Blog
D
DataBreaches.Net
Vercel News
Vercel News
B
Blog
Recent Announcements
Recent Announcements
S
SegmentFault 最新的问题
M
MIT News - Artificial intelligence
爱范儿
爱范儿
博客园 - 【当耐特】
The Cloudflare Blog
H
Help Net Security
云风的 BLOG
云风的 BLOG
P
Proofpoint News Feed
C
Check Point Blog
有赞技术团队
有赞技术团队
Microsoft Security Blog
Microsoft Security Blog
酷 壳 – CoolShell
酷 壳 – CoolShell
freeCodeCamp Programming Tutorials: Python, JavaScript, Git & More

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Trans...
2026-05-08 · via All Articles on Seeking Alpha

Q1: 2026-05-07 Earnings Summary

EPS of -$0.84 misses by $0.22

 | 

Revenue of

$194.52M

(66.78% Y/Y)

beats by $15.90M

BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call May 7, 2026 4:30 PM EDT

Company Participants

Chinmay Shukla - Senior Vice President of Strategic Finance
Neil Kumar - Co-Founder, CEO & Director
Matthew Outten - Chief Commercial Officer
Thomas Trimarchi - CFO & President
Anna Wade - BD & Operations

Conference Call Participants

Samuel Rollenhagen - TD Cowen, Research Division
Mani Foroohar - Leerink Partners LLC, Research Division
Biren Amin - Piper Sandler & Co., Research Division
Cory Kasimov - Evercore ISI Institutional Equities, Research Division
Salim Syed - Mizuho Securities USA LLC, Research Division
Eliana Merle - Barclays Bank PLC, Research Division
Anupam Rama - JPMorgan Chase & Co, Research Division
Derek Archila - Wells Fargo Securities, LLC, Research Division
Kyuwon Choi - Goldman Sachs Group, Inc., Research Division
Lin Tsai - Jefferies LLC, Research Division
Danielle Brill Bongero - Truist Securities, Inc., Research Division
Jason Zemansky - BofA Securities, Research Division
John Boyle - William Blair & Company L.L.C., Research Division

Presentation

Operator

Good afternoon. I will be your conference operator today. [Operator Instructions]

Before we begin, I would like to remind everyone that today's call may contain forward-looking statements within the meaning of the federal securities laws, including, but not limited to, statements about BridgeBio's future operating and financial performance, business plans and prospects and strategy. These statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied in these forward-looking statements.

For a discussion of these risks and uncertainties, please refer to the disclosure in today's earnings release in BridgeBio's periodic reports and SEC filings. All statements made here are based on information available to BridgeBio as of today, and the company undertakes no obligation to update any forward-looking statements made during this call, except as required by law.

With that completed, BridgeBio, you may